| Not Yet Recruiting | Aquarius Pilot Study to Evaluate the New Axonics Trial System NCT07335484 | Axonics, Inc. | N/A |
| Not Yet Recruiting | Tensi+ for Treating Overactive Bladder: A Randomized Controlled Trial NCT07300904 | Stimuli Technology | N/A |
| Recruiting | INOPASE - Performance and Safety Study of a Personalised SNM System NCT07193407 | INOPASE Pty Ltd | N/A |
| Recruiting | Zinc Supplementation With Botulinum Toxin for Overactive Bladder NCT07405554 | Endeavor Health | Phase 2 |
| Not Yet Recruiting | Evaluate the Safety and Efficacy of TRG-200 KIT in Patients With Refractory Overactive Bladder. NCT07391878 | Trigone Pharma Ltd. | Phase 2 |
| Not Yet Recruiting | Efficacy and Safety of 7 Millimeters Vaginal Radiofrequency in Overactive Bladder NCT07279142 | IRCCS San Raffaele | N/A |
| Recruiting | Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women NCT07209397 | InMode MD Ltd. | N/A |
| Recruiting | Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women NCT07473310 | Mansoura University | Phase 4 |
| Recruiting | Comparative Study of the Efficacy of Treatment of Idiopathic Overactive Bladder (OAB) in Children: Oxybutynine NCT07030803 | Centre Hospitalier Universitaire, Amiens | N/A |
| Recruiting | Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB) NCT07195656 | FemPulse Corporation | N/A |
| Not Yet Recruiting | A Prospective Evaluation of a Prescription Digital Therapeutic for Treatment of Overactive Bladder in Women: T NCT07206446 | University of Galway | N/A |
| Recruiting | PMCF Study of the Axonics SNM System Model 5101 (R20) for the Indication of OAB NCT06789406 | Axonics, Inc. | N/A |
| Recruiting | Assessing the Genitourinary Microbiome of Women With Overactive Bladder Undergoing Onabotulinum Toxin Type A I NCT07025044 | Alexis Dieter | — |
| Recruiting | Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladd NCT07416968 | Mansoura University | Phase 4 |
| Recruiting | Early Detection of OAB and Elimination of Negative Impact on Quality of Life NCT07371000 | Institute of Health Information and Statistics of the Czech Republic | N/A |
| Recruiting | Comparing Treatments for Overactive Bladder in Taiwan: A Study of Outcomes NCT07025642 | Mackay Medical College | N/A |
| Completed | Effect of Vaginal Estrogen on Alterations in the Urine Microbiome of Menopausal Women With Overactive Bladder NCT06780163 | Mahidol University | Phase 4 |
| Recruiting | Home-Based Transcutaneous Remotely Monitored Posterior Tibial Neuromodulation NCT07081412 | Ege University | N/A |
| Not Yet Recruiting | Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA Injection NCT06953271 | Women and Infants Hospital of Rhode Island | Phase 4 |
| Recruiting | Evaluating Pumpkin Seed Oil Extract Supplementation on Bladder Function NCT06944392 | Northwestern University | N/A |
| Recruiting | APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women NCT06797245 | Medstar Health Research Institute | N/A |
| Recruiting | Effect of Neuromodulation and Therapeutic Exercise in Urinary Incontinence NCT06783374 | Fundación Universidad Católica de Valencia San Vicente Mártir | N/A |
| Not Yet Recruiting | Cefar URO - Symptomatic Treatment of Overactive Bladder NCT06659536 | DJO UK Ltd | N/A |
| Completed | Ease of Use Study of the FemPulse System NCT06885099 | FemPulse Corporation | N/A |
| Enrolling By Invitation | Transcutaneous Tibial Nerve Stimulation Therapy in Children With Overactive Bladder NCT06765629 | The Children's Hospital of Zhejiang University School of Medicine | N/A |
| Completed | The Role of Urinary ATP in the Diagnosis, Treatment, and Follow-up of Children With Overactive Bladder NCT06785558 | Marmara University | N/A |
| Completed | Electronic Urinary Flowmeter to Improve Accuracy of Bladder Diaries . NCT05702294 | Birmingham Women's and Children's NHS Foundation Trust | N/A |
| Terminated | A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive B NCT04641975 | Astellas Pharma Global Development, Inc. | Phase 3 |
| Completed | The Safety and PK Characteristics of the Co-administration of JLP-2002 and Comparator in Healthy Volunteers NCT04914221 | Jeil Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder NCT04562090 | Astellas Pharma China, Inc. | Phase 4 |
| Completed | Open Label Study to Evaluate the Efficacy of the Home Based Electrical Transcutaneous URIS I in the Treatment NCT05211193 | Stimvia s.r.o. | — |
| Completed | A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Bur NCT03903094 | Astellas Pharma Singapore Pte. Ltd. | — |
| Completed | Transdermal Versus Oral Oxybutynin in Pediatric OAB NCT07081906 | Dr. Lutfi Kirdar Kartal Training and Research Hospital | N/A |
| Completed | Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia NCT03602508 | Astellas Pharma Singapore Pte. Ltd. | — |
| Completed | A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and C NCT03572231 | Astellas Pharma Singapore Pte. Ltd. | — |
| Completed | Vaginal CO2 Laser in Postmenopausal Women With Overactive Bladder Syndrome (OAB) NCT03846895 | National and Kapodistrian University of Athens | N/A |
| Terminated | PTNS vs Botox of Refractory OAB NCT04451382 | Medstar Health Research Institute | — |
| Completed | Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) NCT02294396 | Astellas Pharma Inc | Phase 4 |
| Completed | Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive NCT02216214 | Astellas Pharma Global Development, Inc. | Phase 4 |
| Completed | A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Relea NCT02138747 | Astellas Pharma Global Development, Inc. | Phase 4 |
| Completed | Drug Use Investigation for Toviaz NCT01936870 | Pfizer | — |
| Completed | Vesitirim™ in Men Postmarketing Observational Study NCT01639794 | Astellas Pharma Europe Ltd. | — |
| Completed | SVT-40776 in Patients Suffering From Overactive Bladder Syndrome NCT00507169 | Salvat | Phase 2 |
| Completed | Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder NCT00366002 | Novartis | Phase 4 |
| Completed | Detrol LA In Men With Overactive Bladder. NCT00282932 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 4 |
| Withdrawn | A Study Measuring and Tracking Changes in Overactive Bladder (OAB) Medication NCT01317810 | Astellas Pharma Inc | — |
| Completed | A Phase II Study of KUC-7483 in Patients With Overactive Bladder NCT00742833 | Kissei Pharmaceutical Co., Ltd. | Phase 2 |